Revolution Medicines . Warrant Stock Earnings Reports

Revolution Medicines reported a transformative quarter driven by a positive Phase III (RASolute 302) topline readout for daraxonrasib in previously treated metastatic pancreatic cancer, where the drug showed statistically significant and clinically meaningful improvements in progression-free survival and overall survival versus chemotherapy (reported as a 60% reduction in risk of death and median OS > 1 year). Management is pursuing an NDA filing in the U.S. (including use of the FDA Commissioner’s National Priority Voucher Program), pursuing global filings, and has begun an expanded access program in the U.S. Multiple registrational and late-stage studies are underway or planned across pancreatic cancer (first-line, adjuvant, and combination regimens including zoldonrasib ± daraxonrasib), non–small cell lung cancer (including daraxonrasib and zoldonrasib trials, and an expanded RASolve 301), and colorectal cancer combination efforts. Early-stage assets include RMC-5127 (G12V selective) with a Phase II dose expected in H2 2026, and a preclinical catalytic RAS(ON) inhibitor class (RM-055) planned to enter first-in-human in Q4 2026 that may address resistance mechanisms. The company reported strong investor support allowing a large capital raise; as of quarter end they had ~$1.9B in cash and investments and subsequently raised additional proceeds (~$2.1B net in April). Financials reflect increased investment to accelerate development and commercialization: Q1 R&D and G&A rose materially, net loss widened (Q1 2026 net loss $453.8M), stock‑based compensation was elevated due to a retirement-benefit modification (driving an $80M increase to full-year SBP estimate), and full-year guidance was updated to GAAP operating expenses of $1.7–$1.8B and stock‑based compensation of $260–$280M. Commercial and launch infrastructure is being built out (U.S. sales force nearing onboarding and regional general managers appointed for APAC, Japan, Germany). Management emphasized urgent regulatory and launch preparation and expects to present full RASolute 302 data at ASCO.